Endocyte (ECYT) in Focus: Stock Tanks 14% – Tale of the Tape

Zacks

Endocyte, Inc. (ECYT) saw a big move last session, as the company’s shares fell by nearly14% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This reverses the most recent trend for ECYT as the stock is now up around 7.6% since June 3, 2014.

The company has seen a flat track record when it comes to current year estimate revisions over the past few weeks. However, the consensus for loss estimates has narrowed. This recent price action is discouraging, so make sure to keep a close watch of this firm in the near future, and especially on earnings estimates following the recent slump.

ECYT currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive.

Some better-ranked stocks in the healthcare sector include Aeolus Pharmaceuticals Inc. (AOLS), Aerie Pharmaceuticals, Inc. (AERI) and Ariad Pharmaceuticals Inc. (ARIA). All these stocks hold a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.

Be the first to comment

Leave a Reply